LightNews LightNews
dlontrusk.bsky.social
@dlontrusk.bsky.social
15 followers 17 following 3 posts
Posts Replies Media Videos
Reposted
powelljr.bsky.social
Young adults are growing increasingly economically dislocated - on.ft.com/4qTjjvv via @FT
Young adults are growing increasingly economically dislocated
A disconnected class is taking shape, but is absent from the headline statistics
on.ft.com
November 14, 2025 at 8:46 AM
Reposted
powelljr.bsky.social
Proud to have signed letter from 600+ economists & inequality experts from 70 countries supporting the call for a new Independent Panel on Inequality- an Inequality IPCC- to tackle the inequality emergency- G20 leaders must support this. #G20SouthAfrica www.independent.co.uk/news/south-a...
Top economists call on world leaders to set up an international panel on inequality
Hundreds of top economists and other experts including former U.S. Treasury Secretary Janet Yellen are calling for the world to set up an independent international panel on income and wealth inequalit...
www.independent.co.uk
November 14, 2025 at 4:09 PM
dlontrusk.bsky.social
Really enjoyed the part about fractalisation (if that's a word).

Great read
leonfedden.bsky.social Leon Fedden @leonfedden.bsky.social · May 7
I've wrote my first official post on the subtleties of AI enchanced productivity, from my own experiences, what I've observed, and what I've read recently:

leonfedden.co.uk/blog/2025/05...

#AI #Productivity #LLM #Opinion #ChatGPT
Subtleties of AI Productivity Gains - Leon's Blog
Exploring the nuances in productivity gains when using AI for work
leonfedden.co.uk
September 4, 2025 at 1:13 AM
Reposted
hankgreen.bsky.social
I always said “this is the best year so far in human history to get cancer” and John retorted, “yeah, but next year would have been better.”

Truly ridiculous how right he was…
Two years after starting treatment, about 92% of trial participants randomly assigned to the nivolumab–AVD group were alive without their cancer starting to grow again—a measure known as progression-free survival—compared with 83% in the brentuximab–AVD group. People in the nivolumab–AVD group also had fewer side effects overall and fewer serious side effects, according to findings reported October 17 in the New England Journal of Medicine. The immunotherapy drug nivolumab (Opdivo) should be part of the initial treatment of teens and adults with advanced forms of classic Hodgkin lymphoma, according to updated results from a large NCI-funded clinical trial. In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).
January 13, 2025 at 4:00 AM